[{"data":1,"prerenderedAt":256},["ShallowReactive",2],{"site":3,"pipeline":167,"team":195},{"id":4,"aboutHeadline":5,"aboutIntro":6,"aboutLabel":7,"contactBody":8,"contactCta":9,"contactHeadline":12,"contactLabel":13,"designations":14,"designationsHeadline":22,"designationsLabel":23,"extension":24,"focusAreas":25,"focusHeadline":35,"focusLabel":36,"footerColumns":37,"footerCopyright":70,"footerLegalBlocks":71,"footerLegalLinks":81,"footerLogoMain":91,"footerLogoSub":92,"footerTagline":93,"heroEyebrow":94,"heroPrimaryCta":95,"heroSecondaryCta":97,"heroStats":99,"heroSubtitle":109,"heroTitle":110,"marqueeItems":111,"meta":120,"missionCallout":121,"missionHeadline":122,"missionLabel":96,"missionParagraphs":123,"navCta":126,"navLinks":128,"pipelineHeadline":137,"pipelineLabel":138,"pipelineNote":139,"pipelineStages":140,"seoDescription":162,"seoOgImage":163,"seoTitle":164,"stem":165,"__hash__":166},"site\u002Fsite\u002Findex.yml","The team behind\n*the science.*\n","ZP5 Therapeutics was co-founded by two industry veterans who previously built and sold a company together — bringing decades of combined experience in drug development, regulatory affairs, and clinical pharmacology to one of global health's most pressing problems.","About Us","Whether you're a potential partner, researcher, or investor, we'd love to share what we're working on and explore how we might work together toward better treatments for neglected diseases.",{"label":10,"href":11},"Reach Out","#contact","Want to learn more about\nZero Point Five Therapeutics?\n","Get In Touch",[15,19],{"tag":16,"title":17,"body":18},"FDA Designation","Rare Pediatric Disease Designation","Granted by the FDA in recognition of the serious and life-threatening nature of the condition in patients aged 18 and under. This designation provides eligibility for a Priority Review Voucher upon approval — a significant commercial and humanitarian milestone.",{"tag":16,"title":20,"body":21},"Orphan Drug Designation","Awarded by the FDA's Office of Orphan Products Development for our lead therapeutic candidate. This designation confers seven years of market exclusivity upon approval, tax credits for qualified clinical trials, and waiver of the Prescription Drug User Fee Act application fee.","Recognized at every level\nof *regulatory priority.*\n","Regulatory Designations","yml",[26,29,32],{"title":27,"body":28},"Neglected Tropical Diseases","Targeting parasitic and bacterial infections that afflict hundreds of millions in tropical and subtropical regions with limited access to existing treatments.",{"title":30,"body":31},"Rare & Orphan Conditions","Addressing conditions that affect small patient populations, where the commercial incentive has historically been insufficient to attract pharmaceutical investment.",{"title":33,"body":34},"Drug-Resistant Infections","Developing novel therapeutic strategies to combat the global threat of antimicrobial resistance, which disproportionately impacts resource-limited healthcare settings.","Where our *science* is directed.","Focus Areas",[38,54,62],{"heading":39,"links":40},"Company",[41,44,46,49,52],{"label":42,"href":43},"Mission","#mission",{"label":36,"href":45},"#focus",{"label":47,"href":48},"Pipeline","#approach",{"label":50,"href":51},"Designations","#designations",{"label":53,"href":11},"Contact",{"heading":55,"links":56},"Regulatory",[57,58,59],{"label":17,"href":51},{"label":20,"href":51},{"label":60,"href":61},"ClinicalTrials.gov","https:\u002F\u002Fclinicaltrials.gov",{"heading":53,"links":63},[64,67],{"label":65,"href":66},"contact@zeropointfivetherapeutics.com","mailto:contact@zeropointfivetherapeutics.com",{"label":68,"href":69},"zeropointfivetherapeutics.com","https:\u002F\u002Fzeropointfivetherapeutics.com","© 2026 Zero Point Five Therapeutics, Inc. · All Rights Reserved",[72,75,78],{"heading":73,"body":74},"Forward-Looking Statements","This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the clinical development, regulatory strategy, and potential commercialization of Zero Point Five Therapeutics, Inc.'s product candidates. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks related to clinical trial outcomes, regulatory review and approval, manufacturing, competition, and market conditions. Forward-looking statements speak only as of the date on which they are made, and Zero Point Five Therapeutics, Inc. undertakes no obligation to update or revise any forward-looking statement, except as required by law.",{"heading":76,"body":77},"Regulatory & Clinical Disclaimer","Zero Point Five Therapeutics, Inc.'s lead product candidate is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority for any indication. The safety and efficacy of this investigational compound have not been established. Rare Pediatric Disease Designation and Orphan Drug Designation are granted by the FDA and are not a guarantee of regulatory approval. These designations provide certain development incentives but do not confirm that the product candidate will receive marketing approval or be commercially successful. Information on this website is intended for informational purposes only and does not constitute medical advice, a solicitation for investment, or an offer to sell securities.",{"heading":79,"body":80},"No Offer of Securities","Nothing on this website constitutes an offer to sell, or a solicitation of an offer to buy, any securities of Zero Point Five Therapeutics, Inc. Any offering of securities will be made only pursuant to a formal offering memorandum or other applicable disclosure document in compliance with applicable federal and state securities laws.",[82,85,88],{"label":83,"href":84},"Privacy Policy","\u002Flegal\u002Fprivacy",{"label":86,"href":87},"Terms of Use","\u002Flegal\u002Fterms",{"label":89,"href":90},"Cookie Policy","\u002Flegal\u002Fcookies","Zero Point Five","Therapeutics, Inc.","Developing safe and efficacious treatments\nfor neglected diseases.","Phase 3 Clinical Stage",{"label":96,"href":43},"Our Mission",{"label":98,"href":11},"Get in Touch",[100,103,106],{"number":101,"label":102},"1B+","NTD-Affected People",{"number":104,"label":105},"2B","STH Infections Worldwide",{"number":107,"label":108},"149","Countries with Endemic NTDs","Zero Point Five Therapeutics, Inc. is developing safe and efficacious therapeutic interventions for diseases that have been historically overlooked by mainstream medicine.","Treatments for *neglected* diseases.",[112,113,114,115,116,117,118,119],"Phase 3 Clinical Trial","Safe & Efficacious","Neglected Diseases","Drug Discovery","Global Health","Novel Therapeutics","Patient-First Science","Zero Point Five Therapeutics",{},"\"Developing safe and efficacious treatments for neglected diseases is not just a scientific challenge — it is a moral imperative.\"","Science in service of the *overlooked*.",[124,125],"Neglected diseases disproportionately affect billions of people in low- and middle-income communities, yet they receive a fraction of global pharmaceutical research and development investment. The gap between need and resource is one of the most pressing inequities in modern medicine.","At Zero Point Five Therapeutics, Inc., we are committed to closing that gap — and we have moved beyond early research to the frontlines of clinical validation. Our lead program is now in Phase 3 clinical trials, combining rigorous scientific methodology with a genuine moral urgency to deliver therapeutic solutions that are both safe and highly effective for populations that have been left behind.",{"label":127,"href":11},"Learn More",[129,130,131,132,133,136],{"label":42,"href":43},{"label":36,"href":45},{"label":47,"href":48},{"label":50,"href":51},{"label":134,"href":135},"About","#about",{"label":53,"href":11},"Phase 3. *The final mile.*","Clinical Pipeline","Lead program currently enrolling in Phase 3 pivotal trial across multiple international clinical sites.",[141,145,148,151,155,159],{"label":142,"sublabel":143,"status":144},"Preclinical","Target ID & Lead Opt.","done",{"label":146,"sublabel":147,"status":144},"Phase 1","Safety & PK",{"label":149,"sublabel":150,"status":144},"Phase 2","Proof of Concept",{"label":152,"sublabel":153,"status":154},"Phase 3","Pivotal Trial","active",{"label":156,"sublabel":157,"status":158},"NDA \u002F BLA","Regulatory Filing","future",{"label":160,"sublabel":161,"status":158},"Approval","Market Access","Zero Point Five Therapeutics is developing safe and efficacious therapeutic interventions for neglected tropical diseases, rare & orphan conditions, and drug-resistant infections. Lead program currently in Phase 3.","\u002Fog\u002Fdefault.jpg","ZP5 Therapeutics — Treatments for Neglected Diseases","site\u002Findex","8OfwCKyQgTg28kv-Q_sWpvKqaqTTJpvjGzEKQxRJKUY",[168],{"id":169,"title":170,"body":171,"description":183,"extension":184,"indication":185,"meta":186,"navigation":187,"order":188,"path":189,"programName":190,"seo":191,"stage":152,"status":192,"stem":193,"__hash__":194},"pipeline\u002Fpipeline\u002F01-zp5-9676.md","01 Zp5 9676",{"type":172,"value":173,"toc":178},"minimark",[174],[175,176,177],"p",{},"ZP5-9676 is a novel therapeutic agent in development for the treatment of\nsoil-transmitted helminth infections, which affect more than two billion people\nworldwide and disproportionately impact children in low- and middle-income countries.",{"title":179,"searchDepth":180,"depth":181,"links":182},"",2,3,[],"Lead therapeutic candidate for soil-transmitted helminth (STH) infections, currently enrolling in a Phase 3 pivotal trial across multiple international clinical sites. Granted both Orphan Drug Designation and Rare Pediatric Disease Designation by the FDA.","md","Soil-Transmitted Helminthiasis",{},true,0,"\u002Fpipeline\u002F01-zp5-9676","ZP5-9676",{"description":183},"Enrolling","pipeline\u002F01-zp5-9676","YkTH-1gWlJnctawOIwMrCqe9IltWfftC0qGbuk5xQuk",[196,226],{"id":197,"title":198,"body":199,"description":203,"extension":184,"highlights":212,"linkedin":217,"meta":218,"name":219,"navigation":187,"order":188,"path":220,"photo":221,"photoAlt":222,"seo":223,"stem":224,"__hash__":225},"team\u002Fteam\u002F01-joseph-amprey.md","CEO & Founder",{"type":172,"value":200,"toc":210},[201,204,207],[175,202,203],{},"Dr. Amprey has been in health care for over 23 years, combining clinical training,\nventure capital, and executive leadership across multiple successful biotech ventures.\nMost recently, he was VP and Head of US Medical Affairs at Lupin Pharmaceuticals,\nplaying a key role in the launch of Solosec for the US market.",[175,205,206],{},"Prior to Lupin, he co-founded Symbiomix Therapeutics — a venture-backed company\nacquired by Lupin Pharmaceuticals in 2017 after achieving NDA approval for Solosec™\n— serving as Chief Business Officer and Head of Medical Affairs. He also co-founded\nZyngenia, an antibody-based drug development company focused on breast cancer and\nautoimmune diseases.",[175,208,209],{},"Dr. Amprey's passion for drug development was shaped by his earlier career as a\nventure capitalist. He ran MedImmune Ventures, a $300M corporate venture fund that\nbecame the corporate venture arm of AstraZeneca during his tenure. Dr. Amprey\ncompleted his internship in internal medicine through a joint residency at\nNew York-Presbyterian Hospital and Memorial Sloan-Kettering Cancer Center. He earned\nhis B.S. in Biochemistry from the University of Pennsylvania and received both a\nDoctorate of Immunology and a Medical Degree from Cornell University's Weill Medical\nCollege through the NIH-funded MSTP program, with additional graduate training from\nHarvard's Brigham and Women's Hospital and the Albert Einstein College of Medicine.",{"title":179,"searchDepth":180,"depth":181,"links":211},[],[213,214,215,216],"Cornell Weill \u002F UPenn Biochemistry","NIH MSTP","Symbiomix Co-Founder","MedImmune Ventures ($300M)",null,{},"Joseph Amprey, MD, PhD","\u002Fteam\u002F01-joseph-amprey","\u002Fteam\u002Fjoseph-amprey.jpg","Joseph Amprey, CEO and Founder of ZP5 Therapeutics",{"title":198,"description":203},"team\u002F01-joseph-amprey","tF07SB-4Aw6izzZMZnpliFPawDTSR86Qlyv2Ns0hymk",{"id":227,"title":228,"body":229,"description":233,"extension":184,"highlights":242,"linkedin":217,"meta":247,"name":248,"navigation":187,"order":249,"path":250,"photo":251,"photoAlt":252,"seo":253,"stem":254,"__hash__":255},"team\u002Fteam\u002F02-helen-pentikis.md","CSO & Founder",{"type":172,"value":230,"toc":240},[231,234,237],[175,232,233],{},"Dr. Pentikis brings more than 25 years of experience in the development of new drugs\nand therapeutics. She has represented scientific interests in pharmacology\u002Ftoxicology,\nclinical pharmacology, biopharmaceutics, and regulatory strategy across more than 75\nFDA regulatory meetings, and has been involved in more than 150 clinical studies in\nadult and pediatric patients spanning Phase 1–3 — with deep expertise in\nanti-infectives, women's health, CNS, oncology, and oncology supportive care.",[175,235,236],{},"She co-founded Symbiomix Therapeutics as CSO, leading the scientific strategy through\nits acquisition by Lupin Pharmaceuticals in 2017 following NDA approval for Solosec™.\nPrior to Symbiomix, she served as Head of Clinical Pharmacology at AkaRx Inc., where\nher work on the senior management team contributed to the company's $300M\nacquisition. Dr. Pentikis has also served as Global VP of Pharmacokinetics and\nPharmacodynamics at ICON plc, as a Senior Research Fellow at Sanofi-Aventis, and as\nan FDA Reviewer in the Office of Clinical Pharmacology.",[175,238,239],{},"She holds a B.S. in Biology from Wake Forest University, a Ph.D. in Pharmacology and\nToxicology from the University of Maryland, and completed a Pharmacokinetics\nFellowship at the FDA. She serves as a grant reviewer for the Maryland Innovation\nInitiative and has served on the boards of Metrum Research Group and Redivivus\nTherapeutics.",{"title":179,"searchDepth":180,"depth":181,"links":241},[],[243,244,245,246],"25+ Years Drug Development","75+ FDA Regulatory Meetings","150+ Clinical Studies","80+ Publications",{},"Helen Pentikis, PhD",1,"\u002Fteam\u002F02-helen-pentikis","\u002Fteam\u002Fhelen-pentikis.jpg","Helen Pentikis, CSO and Founder of ZP5 Therapeutics",{"title":228,"description":233},"team\u002F02-helen-pentikis","EBQchgm7CwlXoBBXn6urjoe0HMYDB-MQge71ue0KViU",1777662005155]